Metabolomic sensor systems

Value proposition

Introduce 10 cost saving diagnostic tests (e.g. PSA) using metabolomic platforms into a clinical environment by 2022.

The opportunity

Tapping the metabolome goes beyond a simple positive/negative test but inform therapeutic regimen based on type and stage of the disease. Metabolomics is relevant to a large number of Canadian companies across industrial sectors that need to understand the interplay between biologically-derived organic chemicals- pharmacology, pre-clinical drug trials, toxicology, transplant monitoring, newborn screening and clinical chemistry. Canada could capture a significant share of the market given its pre-eminence in this emerging field. Canada benefits from the presence of multinationals that play in the supply chain. Potential customers for metabolomics-based sensing systems include major pharma companies, contract research organizations, agricultural, veterinary and petrochemical industries; local and regional startup companies focused in the metabolomics field; major

Contact

Dr. Prasanna S. Bhomkar, Research Officer
11421 Saskatchewan Drive
NINT Room 2-021E
Edmonton, Alberta T6G 2M9

Telephone: 780-641-1693
Fax: 780-641-1601
Email: Prasanna.Bhomkar@nrc-cnrc.gc.ca